Early initiation of ambroxol treatment diminishes neurological manifestations of type 3 Gaucher disease: A long-term outcome of two siblings

Marked elevation of plasma chitotriosidase activity. A novel hallmark of Gaucher disease.

Carla E. M. Hollak, Sonja van Weely, M. H. van Oers et al. · Journal of Clinical Investigation · 1994 · 899 citations · Full text

Clinical Symptoms, Immunology, Glycobiology +17

Identification and Characterization of Ambroxol as an Enzyme Enhancement Agent for Gaucher Disease

Gustavo Maegawa, Michael B. Tropak, Justin Buttner et al. · Journal of Biological Chemistry · 2009 · 328 citations · Full text

Analysis and Classification of 304 Mutant Alleles in Patients with Type 1 and Type 3 Gaucher Disease

Vuk Koprivica, Deborah L. Stone, Joseph K. Park et al. · The American Journal of Human Genetics · 2000 · 324 citations · Full text

Type 1, Genetic Diseases, Allelic Variant +10

Randomized, controlled trial of miglustat in Gaucher's disease type 3

Raphael Schiffmann, Edmond J. FitzGibbon, Chris Harris et al. · Annals of Neurology · 2008 · 232 citations · Full text

Ambroxol chaperone therapy for neuronopathic Gaucher disease: A pilot study

Aya Narita, Kentarou Shirai, Shinji Itamura et al. · Annals of Clinical and Translational Neurology · 2016 · 212 citations · Full text